Fresenius (ETR:FRE) Rating Reaffirmed
Jefferies & Company Inc. now has a EUR 60.00 Estimated Target Price on shares of Fresenius (ETR:FRE). The Estimated Target Price would indicate a potential downside of -5.62% from the price per share of Fresenius (ETR:FRE). This rating was shown in an interesting research report on Thursday, 17 December.
From a total of 12 analysts covering Fresenius (ETR:FRE) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is €74 while the lowest target price is €60. The mean of all analyst targets is €66.71 with a 4.79% above today’s (€63.66) stock price. Fresenius was the topic of 23 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Independent Research maintained shares on November 3 with “Hold” rating. Commerzbank upgraded shares to “Add” rating and €69 target share price in a report from a September 15. Bankhaus Lampe maintained FRE stock in a recent report from October 31 with “Hold” rating. Oddo & Cie upgraded the rating on August 27. Oddo & Cie has a “Buy” rating and a €67 price target on shares. Finally, S&P Research upgraded the stock to “Buy” rating in a report issued on an October 30.
The stock increased 0.78% or EUR 0.49 on December 16, striking EUR 63.66. Approximately 1.26 million shares of stock traded hands or 14.55% up from the average. Fresenius SE & Co KGaA (ETR:FRE) has risen 6.00% since November 17, 2015 and is uptrending. It has outperformed by 8.62% the S&P500.
Fresenius SE & Co KGaA is a health care company. The company has a market cap of 34.03 billion EUR. It operates in the healthcare sector and offers services and products for dialysis, hospitals and outpatient medical care. It has 27.97 P/E ratio. It focuses on the hospital activities and offers engineering and services for hospitals and other health care facilities.